摘要 |
The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. |
申请人 |
KARYOPHARM THERAPEUTICS, INC. |
发明人 |
SANDANAYAKA, VINCENT, P.;SHACHAM, SHARON;KAUFFMAN, MICHAEL;SHECHTER, SHARON;MCCAULEY, DILARA;LANDESMAN, YOSEF;SENAPEDIS, WILLIAM;SAINT-MARTIN, JEAN-RCHARD |